325 related articles for article (PubMed ID: 25962717)
21. Population pharmacokinetics and covariate analysis of Sym004, an antibody mixture against the epidermal growth factor receptor, in subjects with metastatic colorectal cancer and other solid tumors.
Alifrangis L; Schoemaker R; Skartved NJ; Hald R; Montagut C; Kopetz S; Tabernero J; Kragh M; Wade JR
J Pharmacokinet Pharmacodyn; 2020 Feb; 47(1):5-18. PubMed ID: 31679083
[TBL] [Abstract][Full Text] [Related]
22. MET amplification in metastatic colorectal cancer: an acquired response to EGFR inhibition, not a de novo phenomenon.
Raghav K; Morris V; Tang C; Morelli P; Amin HM; Chen K; Manyam GC; Broom B; Overman MJ; Shaw K; Meric-Bernstam F; Maru D; Menter D; Ellis LM; Eng C; Hong D; Kopetz S
Oncotarget; 2016 Aug; 7(34):54627-54631. PubMed ID: 27421137
[TBL] [Abstract][Full Text] [Related]
23. Potential biomarkers for anti-EGFR therapy in metastatic colorectal cancer.
Yang J; Li S; Wang B; Wu Y; Chen Z; Lv M; Lin Y; Yang J
Tumour Biol; 2016 Sep; 37(9):11645-11655. PubMed ID: 27422777
[TBL] [Abstract][Full Text] [Related]
24. Beyond KRAS: a new approach in metastatic colorectal cancer.
Winder T; Lenz HJ
Lancet Oncol; 2010 Aug; 11(8):706-7. PubMed ID: 20619738
[No Abstract] [Full Text] [Related]
25. Targeting mechanisms of resistance to anti-EGF receptor therapy in KRAS wild-type colorectal cancer: the path to more personalized medicine.
Fakih M
Future Oncol; 2013 Apr; 9(4):551-60. PubMed ID: 23560377
[TBL] [Abstract][Full Text] [Related]
26. [Relationship between the Incidence of Hypomagnesemia and Acneiform Rash and the Therapeutic Effect of Anti-EGFR Monoclonal Antibody in Patients with Metastatic Colorectal Cancer].
Fujii H; Iihara H; Ishihara M; Matsuhashi N; Takahashi T; Yoshida K; Itoh Y
Gan To Kagaku Ryoho; 2016 Feb; 43(2):229-33. PubMed ID: 27067688
[TBL] [Abstract][Full Text] [Related]
27. Panitumumab in the treatment of colon cancer: A biomarker dilemma.
Scott A; Messersmith WA; Jimeno A; Davies SL
Drugs Today (Barc); 2014 Oct; 50(10):679-90. PubMed ID: 25374966
[TBL] [Abstract][Full Text] [Related]
28. MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations.
Arena S; Siravegna G; Mussolin B; Kearns JD; Wolf BB; Misale S; Lazzari L; Bertotti A; Trusolino L; Adjei AA; Montagut C; Di Nicolantonio F; Nering R; Bardelli A
Sci Transl Med; 2016 Feb; 8(324):324ra14. PubMed ID: 26843189
[TBL] [Abstract][Full Text] [Related]
29. Epidermal growth factor receptor mutation mediates cross-resistance to panitumumab and cetuximab in gastrointestinal cancer.
Braig F; März M; Schieferdecker A; Schulte A; Voigt M; Stein A; Grob T; Alawi M; Indenbirken D; Kriegs M; Engel E; Vanhoefer U; Grundhoff A; Loges S; Riecken K; Fehse B; Bokemeyer C; Binder M
Oncotarget; 2015 May; 6(14):12035-47. PubMed ID: 26059438
[TBL] [Abstract][Full Text] [Related]
30. Co-targeting of EGFR and autophagy signaling is an emerging treatment strategy in metastatic colorectal cancer.
Koustas E; Karamouzis MV; Mihailidou C; Schizas D; Papavassiliou AG
Cancer Lett; 2017 Jun; 396():94-102. PubMed ID: 28323034
[TBL] [Abstract][Full Text] [Related]
31. EGFR Downregulation after Anti-EGFR Therapy Predicts the Antitumor Effect in Colorectal Cancer.
Okada Y; Kimura T; Nakagawa T; Okamoto K; Fukuya A; Goji T; Fujimoto S; Sogabe M; Miyamoto H; Muguruma N; Tsuji Y; Okahisa T; Takayama T
Mol Cancer Res; 2017 Oct; 15(10):1445-1454. PubMed ID: 28698359
[TBL] [Abstract][Full Text] [Related]
32. Sym004-induced EGFR elimination is associated with profound anti-tumor activity in EGFRvIII patient-derived glioblastoma models.
Keir ST; Chandramohan V; Hemphill CD; Grandal MM; Melander MC; Pedersen MW; Horak ID; Kragh M; Desjardins A; Friedman HS; Bigner DD
J Neurooncol; 2018 Jul; 138(3):489-498. PubMed ID: 29564747
[TBL] [Abstract][Full Text] [Related]
33. Sym004: Truly a New Level of Anti-EGFR Treatment?
Stintzing S; Heinemann V
Cancer Discov; 2015 Jun; 5(6):578-80. PubMed ID: 26037914
[TBL] [Abstract][Full Text] [Related]
34. A First-in-Human Phase I Study of GC1118, a Novel Anti-Epidermal Growth Factor Receptor Antibody, in Patients with Advanced Solid Tumors.
Oh DY; Lee KW; Han SW; Kim JW; Shin JW; Jo SJ; Won J; Hahn S; Lee H; Kim WH; Bang YJ
Oncologist; 2019 Aug; 24(8):1037-e636. PubMed ID: 31164456
[TBL] [Abstract][Full Text] [Related]
35. Sym004, a novel anti-EGFR antibody mixture, augments radiation response in human lung and head and neck cancers.
Huang S; Peet CR; Saker J; Li C; Armstrong EA; Kragh M; Pedersen MW; Harari PM
Mol Cancer Ther; 2013 Dec; 12(12):2772-81. PubMed ID: 24130052
[TBL] [Abstract][Full Text] [Related]
36. The Best. First. Anti-EGFR before anti-VEGF, in the first-line treatment of RAS wild-type metastatic colorectal cancer: from bench to bedside.
Zaniboni A; Formica V
Cancer Chemother Pharmacol; 2016 Aug; 78(2):233-44. PubMed ID: 27091467
[TBL] [Abstract][Full Text] [Related]
37. [Panitumumab].
Musch A
Med Monatsschr Pharm; 2008 Apr; 31(4):122-6. PubMed ID: 18497243
[TBL] [Abstract][Full Text] [Related]
38. Acquired resistance to EGFR-targeted therapies in colorectal cancer.
Van Emburgh BO; Sartore-Bianchi A; Di Nicolantonio F; Siena S; Bardelli A
Mol Oncol; 2014 Sep; 8(6):1084-94. PubMed ID: 24913799
[TBL] [Abstract][Full Text] [Related]
39. Association between EGFR gene polymorphisms, skin rash and response to anti-EGFR therapy in metastatic colorectal cancer patients.
Jaka A; Gutiérrez-Rivera A; Ormaechea N; Blanco J; La Casta A; Sarasqueta C; Izeta A; Tuneu A
Exp Dermatol; 2014 Oct; 23(10):751-3. PubMed ID: 25039761
[TBL] [Abstract][Full Text] [Related]
40. Overcoming Resistance to Anti-EGFR Therapy in Colorectal Cancer.
Dienstmann R; Salazar R; Tabernero J
Am Soc Clin Oncol Educ Book; 2015; ():e149-56. PubMed ID: 25993166
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
